After cancer initiation through Wnt signaling deregulation, KRAS and PTEN mutations in normal-weight individuals can be advantageous; however, such mutations in high-BMI individuals are less advantageous because the survival and proliferative pathways supported by such mutations are substituted by obesity-induced signaling. The gene discussed is KRAS; the disease is cancer.